GoAI
Get started
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc.

GLUE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$14.30

−$0.48 · -3.25%

Aug 21, 4:00 PM ET

GLUE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

75

Undervalued

Momentum

89

Strong Up

Sentiment

68

Bullish

Risk resilience

49

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Markus Warmuth
Listed since
Jun 24, 2021
Employees
173

Market position

Day range

Current $14.30

52-week range

Current $14.30

Open
$14.80
Previous close
$14.78
Volume
969.16K
0.79× average
Average volume
1.22M
Average daily volume
Market cap
1.21B USD
Beta
1.53
Market reference 1
50-day average
$19.9829
-28.44% below average
200-day average
$18.4864
-22.65% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-6.56×
P/B (TTM)
2.5×
P/S (TTM)
42.05×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
92.94%
Operating margin
-633.04%
Net margin
-560.85%

Financial health

Debt / equity
0.08×
Altman Z-score
2.54
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends113%33%-47%-127%Gross margin, FY2024: 89.26%Gross margin, FY2025: 93.24%Operating margin, FY2024: -107.26%Operating margin, FY2025: -43.83%Net margin, FY2024: -96.14%Net margin, FY2025: -31.23%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 89.26%. Gross margin FY2025 93.24%. Operating margin FY2024 -107.26%. Operating margin FY2025 -43.83%. Net margin FY2024 -96.14%. Net margin FY2025 -31.23%.

Income trends

Revenue

123.67M USD+63.54%

Operating income

−54.21M USD+33.17%

Net income

−38.63M USD+46.87%
Income trends across reported periods150.37M USD43.58M USD−63.22M USD−170.01M USDRevenue, FY2024: 75.62M USDRevenue, FY2025: 123.67M USDOperating income, FY2021: −72.88M USDOperating income, FY2022: −112.38M USDOperating income, FY2023: −143.31M USDOperating income, FY2024: −81.11M USDOperating income, FY2025: −54.21M USDNet income, FY2021: −73.96M USDNet income, FY2022: −108.5M USDNet income, FY2023: −135.35M USDNet income, FY2024: −72.7M USDNet income, FY2025: −38.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 75.62M USD. Revenue FY2025 123.67M USD. Operating income FY2021 −72.88M USD. Operating income FY2022 −112.38M USD. Operating income FY2023 −143.31M USD. Operating income FY2024 −81.11M USD. Operating income FY2025 −54.21M USD. Net income FY2021 −73.96M USD. Net income FY2022 −108.5M USD. Net income FY2023 −135.35M USD. Net income FY2024 −72.7M USD. Net income FY2025 −38.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue123.67M USD75.62M USD———
Cost of goods sold8.36M USD8.12M USD6.22M USD——
Gross profit115.32M USD67.5M USD−6.22M USD——
Research and development141.5M USD121.56M USD105.05M USD85.06M USD57.16M USD
Selling, general, and administrative36.38M USD35.17M USD32.04M USD27.32M USD15.73M USD
Operating expenses169.52M USD148.61M USD137.09M USD112.38M USD72.88M USD
Interest income12.94M USD10.57M USD9.33M USD3.76M USD46K USD
Interest expense———3.76M USD—
Depreciation and amortization8.36M USD8.12M USD6.22M USD3.75M USD2.13M USD
Operating income−54.21M USD−81.11M USD−143.31M USD−112.38M USD−72.88M USD
Net income−38.63M USD−72.7M USD−135.35M USD−108.5M USD−73.96M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+2091.38%
11 comparable reports
Latest EPS result
-0.43
Estimate -0.38 · Miss by 13.02%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.660.23-0.2-0.63Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 0.23, estimate 0.016, surprise +1379.10%, Beat. Q2 2025, reported May 8, 2025: actual 0.57, estimate -0.003, surprise +21690.91%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.15, estimate -0.377, surprise +60.19%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.33, estimate -0.366, surprise +9.92%, Beat. Q1 2026, reported Mar 17, 2026: actual -0.54, estimate -0.352, surprise -53.61%, Miss. Q2 2026, reported May 7, 2026: actual -0.45, estimate -0.28, surprise -60.71%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.43, estimate -0.38, surprise -13.02%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.364, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates91.5M61.79M32.09M2.38MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 60.65M USD, estimate 46.67M USD, surprise +29.95%, Beat. Q2 2025, reported May 8, 2025: actual 84.93M USD, estimate 13.57M USD, surprise +526.01%, Beat. Q3 2025, reported Aug 7, 2025: actual 23.19M USD, estimate 7.77M USD, surprise +198.37%, Beat. Q4 2025, reported Nov 6, 2025: actual 12.77M USD, estimate 15.51M USD, surprise -17.66%, Miss. Q1 2026, reported Mar 17, 2026: actual 2.8M USD, estimate 15.55M USD, surprise -82.00%, Miss. Q2 2026, reported May 7, 2026: actual 4.2M USD, estimate 10.95M USD, surprise -61.65%, Miss. Q3 2026, reported Aug 6, 2026: actual 9M USD, estimate 12.91M USD, surprise -30.31%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 18.89M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$26.67

86.50% upside
Past 12 months12-month forecast

Price history unavailable

High $28.00Average $26.67Low $25.00

GLUE news

defenseworld.net

Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Dimensional Fund Advisors LP boosted its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) by 83.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission…

Read source
zacks.com

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.

Read source
globenewswire.com

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies,…

Read source
globenewswire.com

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of…

Read source
fool.com

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains.

Read source
seekingalpha.com

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential

Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for…

Read source

GLUE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding GLUE

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
42.31M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
32.79M
Weight
0.29%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
28.06M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
12.99M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
10.19M
Weight
0.07%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Avantis U.S. Small Cap Value ETF logoAvantis U.S. Small Cap Value ETFAVUV
Market value
7.74M
Weight
0.02%
AUM
31.27B USD
Expense ratio
0.25%
Price / 1D
$126.45+0.66%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
6.87M
Weight
0.04%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
6.51M
Weight
0.06%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%

Continue in GoAI

Research GLUE

research.disclaimer